Pyridostigmine to Reduce the duration of postoperative Ileus after Colorectal surgery (PyRICo-RCT): randomized clinical trial
British Journal of Surgery · 2024
DOI: 10.1093/bjs/znae121 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift British Journal of Surgery, 2024. Verfasst von Luke Traeger und 6 weiteren Autor:innen. Beteiligte Einrichtung: Colorectal Unit, Department of Surgery, Royal Adelaide Hospital, Adelaide, South Australia, Australia. Hauptthemen laut MEDLINE: Ileus, Postoperative Complications, Cholinesterase Inhibitors, Pyridostigmine Bromide. Die Arbeit wurde bisher 6-mal zitiert (Crossref). Gefördert von: RAH, Royal Australasian College of Surgeons, University of Adelaide Research Training Program Stipend.
Abstract (Originalsprache)
Background
Postoperative ileus, driven by the cholinergic anti-inflammatory pathway, is the most common complication in patients undergoing colorectal surgery. By inhibiting acetylcholinesterase, pyridostigmine can potentially modulate the cholinergic anti-inflammatory pathway and accelerate gastrointestinal recovery. This study aimed to assess the efficacy of pyridostigmine in improving gastrointestinal recovery after colorectal surgery.
Methods
This double-blinded RCT enrolled adult patients undergoing elective colorectal surgery at two hospitals in South Australia. Patients were randomized to 60 mg oral pyridostigmine or placebo twice daily starting 6 h after surgery until the first passage of stool. The primary outcome was GI-2, a validated composite measure of time to first stool and tolerance of oral diet. Secondary outcomes included incidence of postoperative ileus (defined as GI-2 greater than 4 days), duration of hospital stay, and 30-day complications, evaluated by intention-to-treat univariate analysis.
Results
Of 130 patients recruited (mean(s.d.) age 58.4(16.4) years; 73 men, 56%), 65 were allocated to each arm. The median GI-2 was 1 day shorter with pyridostigmine compared with placebo (2 (i.q.r. 1–3) versus 3 (2–4) days; P = 0.015). However, there were no significant differences in postoperative ileus (17.2 versus 21.5%; P = 0.532) or duration of hospital stay (median 5 (i.q.r. 4–8.75) versus 5 (4–7.5) days; P = 0.921). Similarly, there were no significant differences in overall complications, anastomotic leak, cardiac complications, or patient-reported side effects.
Conclusion
Pyridostigmine resulted in a quicker return of GI-2 and was well tolerated. Larger multicentre studies are required to determine the optimal dosing and evaluate the impact of pyridostigmine in different surgical settings. Registration number: ACTRN12621000530820 (https://anzctr.org.au).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Colorectal Unit, Department of Surgery, Royal Adelaide Hospital, Adelaide, South Australia, Australia.
- Adelaide Medical School, Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, South Australia, Australia.
ORCID-Profile: Luke Traeger, Sergei Bedrikovetski, Tarik Sammour
Förderung
- RAH
- Royal Australasian College of Surgeons
- University of Adelaide Research Training Program Stipend
- Central Adelaide Local Health Network CEO CRIPS
Zitieren
APA
Traeger, L., Bedrikovetski, S., Fitzsimmons, T., Nguyen, T. M., Moore, J. W., Lewis, M., & Sammour, T. (2024). Pyridostigmine to Reduce the duration of postoperative Ileus after Colorectal surgery (PyRICo-RCT): randomized clinical trial. British Journal of Surgery. https://doi.org/10.1093/bjs/znae121
Vancouver
Traeger L, Bedrikovetski S, Fitzsimmons T, Nguyen TM, Moore JW, Lewis M, et al. Pyridostigmine to Reduce the duration of postoperative Ileus after Colorectal surgery (PyRICo-RCT): randomized clinical trial. British Journal of Surgery. 2024. doi:10.1093/bjs/znae121
BibTeX
@article{Traeger2024,
author = {Traeger, Luke and Bedrikovetski, Sergei and Fitzsimmons, Tracy and Nguyen, Thuy-My and Moore, James W and Lewis, Mark and Sammour, Tarik},
title = {Pyridostigmine to Reduce the duration of postoperative Ileus after Colorectal surgery (PyRICo-RCT): randomized clinical trial},
journal = {British Journal of Surgery},
year = {2024},
doi = {10.1093/bjs/znae121}
}
EUVIMED